Literature DB >> 11791130

Extended-spectrum beta-lactamase-producing Enterobacteriaceae strains in community-acquired bacteremia in Southern Israel.

Abraham Borer1, Jacob Gilad, Galia Menashe, Nechama Peled, Klaris Riesenberg, Francisc Schlaeffer.   

Abstract

BACKGROUND: In recent years, extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae have emerged in many hospitals worldwide. The increasing dissemination and long-term carriage of these organisms within the community carry tremendous implications on the empirical therapy of community-acquired infection. MATERIAL/
METHODS: To evaluate the prevalence and clinical features of community-acquired bacteremia involving ESBL-producing Enterobacteriaceae in southern Israel (ESBL-P) we retrospectively studied all Enterobacteriaceae bacteremias during an 8-month period in the Negev region using medical and laboratory records. Antibiotic susceptibility was determined using the disk-diffusion method. ESBL production was determined using an E-test ESBL strip. Cases involving ESBL-P were compared to those involving non-producing strains (ESBL-NP) using the chi-square test.
RESULTS: In all, 187 Enterobacteriaceae bacteremias were detected, of which 119 were community-acquired (63.6%). ESBL-P were found in six cases (5%) which are described herein in greater detail. Patients with ESBL-P bacteremia were older, and were more likely to stay in the intensive-care unit. Urinary catheterization and bed-ridden conditions were significant risk factors for ESBL-P. ESBL-P strains were significantly resistant to nearly all antibiotic agents except for imipienem and piperacillin-tazobactam as opposing to ESBL-NP. Patients with ESBL-P bacteremia were more likely to suffer from complications and had a higher mortality.
CONCLUSIONS: This paper is the first to describe community-acquired Enterobacteriaceae bacteremia involving ESBL-P strains in Israel. Although the exact prevalence of these organisms in Israel is currently unknown, our findings suggest that ESBL-producers have already begun to disseminate in our community.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11791130

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  15 in total

1.  Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients.

Authors:  Jesús Rodríguez-Baño; Maria Dolores Navarro; Luisa Romero; Luis Martínez-Martínez; Miguel A Muniain; Evelio J Perea; Ramón Pérez-Cano; Alvaro Pascual
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

2.  Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients.

Authors:  R Colodner; W Rock; B Chazan; N Keller; N Guy; W Sakran; R Raz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-02-19       Impact factor: 3.267

3.  Clinical and molecular analysis of extended-spectrum {beta}-lactamase-producing enterobacteria in the community setting.

Authors:  Corinne Arpin; Véronique Dubois; Jeanne Maugein; Jacqueline Jullin; Brigitte Dutilh; Jean-Philippe Brochet; Gilberte Larribet; Isabelle Fischer; Claudine Quentin
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

4.  Therapeutic challenges of ESBLS and AmpC beta-lactamase producers in a tertiary care center.

Authors:  Naveen Grover; A K Sahni; S Bhattacharya
Journal:  Med J Armed Forces India       Date:  2012-07-17

5.  Antimicrobial resistance status and prevalence rates of extended spectrum beta-lactamase (ESBL) producers isolated from a mixed human population.

Authors:  Ruth A Afunwa; Damian C Odimegwu; Romanus I Iroha; Charles O Esimone
Journal:  Bosn J Basic Med Sci       Date:  2011-05       Impact factor: 3.363

6.  Extended Spectrum Beta-lactamase Detection in Gram-negative Bacilli of Nosocomial Origin.

Authors:  Dechen C Tsering; Shyamasree Das; Luna Adhiakari; Ranabir Pal; Takhellambam Sk Singh
Journal:  J Glob Infect Dis       Date:  2009-07

7.  Screening of clinical, food, water and animal isolates of Escherichia coli for the presence of blaCTX-M extended spectrum beta-lactamase (ESBL) antibiotic resistance gene loci.

Authors:  John E Moore; Miyuki Watabe; B Cherie Millar; Anne Loughrey; Mark McCalmont; Colin E Goldsmith; J C Neville Heaney; Tom Buckley; Claire Egan; David A McDowell; M Ann S McMahon; James S G Dooley; Jiru Xu; Paul J Rooney
Journal:  Ulster Med J       Date:  2010-05

8.  Prevalence of community-occurring extended spectrum beta-lactamase-producing Enterobacteriaceae in Brazil.

Authors:  Luciene A R Minarini; Ana C Gales; Izabel C V Palazzo; Ana Lúcia C Darini
Journal:  Curr Microbiol       Date:  2007-04-24       Impact factor: 2.188

9.  Multilocus sequence typing of uropathogenic ESBL-producing Escherichia coli isolated in a Brazilian community.

Authors:  Luciene A R Minarini; Ilana L B C Camargo; André Pitondo-Silva; Ana Lúcia C Darini
Journal:  Curr Microbiol       Date:  2007-09-25       Impact factor: 2.188

10.  Epidemiology of bacteremia episodes in a single center: increase in Gram-negative isolates, antibiotics resistance, and patient age.

Authors:  D Marchaim; R Zaidenstein; T Lazarovitch; Y Karpuch; T Ziv; M Weinberger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-06-05       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.